However, increasing studies pointed out that Cilengitide at low concentrations promotes tumor angiogenesis rather than inhibiting it, which is due to low-dose Cilengitide can activate Rab-4-mediaed VEGFR2 recycling pathway. This evidence concerns the gene KDR and neoplasm.